Plenary Lectures

 

Opening Plenary Speaker


Dr. Ann L. Lee

Head of Cell Therapy Development & Operations

Bristol-Myers Squibb Company

Sunday, June 21, 2020

"Chromatographic Innovations for Cell Therapies"

Ann L. Lee has 30+ years of bio/pharma experience.  She is currently Head of Cell Therapy Development & Operations for Bristol Myers Squibb, Inc.  She was Executive VP of Technical Operations at Juno Therapeutics, acquired by Celgene, acquired by BMS. Previously, Ann was Senior VP at Genentech and Global Head of Pharma Technical Development at Roche responsible for delivering all modalities in the R&D pipeline and providing technical support for commercial products globally.  Prior, Ann worked at Merck Research Labs in several leadership positions in vaccine development, and was VP of Chemical Technology and Engineering in the Merck Manufacturing Division. Ann has a BSChE degree from Cornell, and a Ph.D in bio/chemical engineering from Yale, where she studied with Csaba Horvath. She is an elected member of the National Academy of Engineering, the American Academy of Arts and Sciences, and the American Institute of Medical and Biological Engineering.  She is a Board of Directors member for AIChE, and for Alliance of Regenerative Medicine.   She was named 150 Most Influential Women in Business in Bay Area Business.  Over the course of her career, Ann has contributed to the development and commercialization of 23 new medicines and vaccines.

 

Opening Plenary Speaker


Professor Steven A. Soper

Foundation Distinguished Professor

Department of Chemistry, Department of Mechanical Engineering, and Bioengineering Program (KU-L);

Department of Cancer Biology (KUMC)

University of Kansas

Sunday, June 21, 2020

"Nanoscale Electrophoresis using Polymer-based Columns: Potential Application for Single-molecule Sequencing"

Prof. Steven A. Soper received his Ph.D. from the University of Kansas in 1989 followed by a Postdoctoral Fellowship at Los Alamos National Laboratory, where he worked on single-molecule detection for high speed sequencing of the human genome. In 1991, he joined the faculty at Louisiana State University (LSU) within the Department of Chemistry, where he filled the William H. Pryor Distinguished Chair of Chemistry. Prof. Soper also held joint appointments in Mechanical Engineering and Biological Sciences. While at LSU, he founded the Center of BioModular Multi-Scale Systems for Precision Medicine, which has as its primary charge to develop enabling and transformative tools for making health-related measurements from rare disease markers, such as liquid biopsy markers, with full process automation. This Center has recently been awarded funding from the National Institutes of Health as part of their Biotechnology Resource Center Program (funded through the National Institute of Biomedical Imaging and Bioengineering). In 2011, Prof. Soper accepted a position within the Department of Biomedical Engineering and Department of Chemistry at the University of North Carolina, Chapel Hill. Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently the Editor of the Americas for the Analyst and on the Editorial Board for Journal of Fluorescence and Journal of Micro- and Nanosystems. Prof. Soper is also serving as a permanent Member of the Nanotechnology study panel with the National Institutes of Health. As a result of his efforts, Prof. Soper has secured extramural funding totaling >$93M, has published over 245 peer-reviewed manuscripts (h index = 66; 15,289 citations); 31 book chapters and 71 peer-reviewed conference proceeding papers, and is the author of 12 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. Soper recently founded a second company, Digital NanoGenetics (DNG), which is seeking to market a new DNA/RNA single-molecule sequencing platform. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 46 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 15 researchers.

 

Closing Plenary Speaker


Professor Dr. Michael Lämmerhofer

Professor

Pharmaceutical (Bio-)Analysis

Institute of Pharmaceutical Sciences

University Tuebingen

Thursday, June 25, 2020

"Lipidomics in Clinical Research"

Michael Lämmerhofer is Full Professor (W3) for Pharmaceutical (Bio-)Analysis at the University of Tübingen, Germany (since 2011). He graduated in Pharmaceutical Sciences in 1992 and earned his PhD in Pharmaceutical Chemistry in 1996 at the University of Graz, Austria (Supervisor: Prof. Wolfgang Lindner). Between 1997 and 2011 he was assistant professor and since 2002 associate professor at the University of Vienna, Department of Analytical Chemistry. From 1999-2000 he spent a year of research as post-doc at the Department of Chemistry of the University of California, Berkeley with Prof. Frantisek Šveč. Since 2007, he is associate editor of Journal of Separation Science. His research interests include the development of functionalized separation materials (chiral stationary phases, mixed-mode phases, chemo- & bioaffinity materials, nanoparticles, monoliths), metabolomics and lipidomics, pharmaceutical analysis (impurity profiling, enantioselective analytics), multidimensional separations and biopharmaceuticals analysis (peptides, oligos, proteins, plasmids).

 

Closing Plenary Speaker


Professor Dr. Guowang Xu

Dalian Institute of Chemical Physics, Chinese Academy of Sciences

Thursday, June 25, 2020

"LC-MS-based Metabolomics Methods and Their Applications in Studying the Metabolic Reprogramming of Diseases"

Prof. Dr. Guowang Xu is the administrative vice-director of Biotechnology Division, and director of CAS Key Laboratory of Separation Science for Analytical Chemistry in Dalian Institute of Chemical Physics, Chinese Academy of Sciences.